Breaking Finance News

CytoDyn (OTCMKTS:CYDY) price target increased to $1.60, issued a research note earlier today by Rodman & Renshaw

CytoDyn (OTCMKTS:CYDY) had its target price upped to $1.60 by Rodman & Renshaw in an issued report issued 10/6/2016. The new stock price target indicates a possible upside of 1.39% based on the company's last closing price.

Only yesterday CytoDyn (OTCMKTS:CYDY) traded -2.76% lower at $0.67. CYDY’s 50-day average is $0.89 and its 200-day moving average is $1.04. With the last stock close price down -35.75% relative to the two hundred day average, compared with the Standard & Poor's 500 Index which has decreased -0.01% over the same time. 336,914 shares of the stock were exchanged, up from an avg. volume of 252,666

Recent Performance Chart

CytoDyn (OTCMKTS:CYDY)

With a total market value of $0, CytoDyn has 52 week low of $0.63 and a one year high of $1.57 .

Brief Synopsis On CytoDyn (OTCMKTS:CYDY)

CytoDyn Inc. is a clinical-stage biotechnology company. The Company is focused on the clinical development and commercialization of humanized monoclonal antibodies to treat Human Immunodeficiency Virus (HIV) infection. The Company's lead product candidate, PRO 140, belongs to a class of HIV therapies known as entry inhibitors that block HIV from entering into and infecting certain cells. The Company's product pipeline also includes Cytolin and CytoFeline. Cytolin is a mouse monoclonal antibody developed to identify a specific type of immune cell called a cytotoxic T cell, or cytotoxic T lymphocyte (CTL). CytoFeline is an anti-lymphocyte function-associated antigen-1 (LFA-1) antibody for the treatment of Feline Immunodeficiency Virus (FIV) infection. PRO 140 blocks HIV from entering a cell by binding to a molecule called C-C chemokine receptor type 5 (CCR5). The Company has finished Phase II clinical trials for PRO 140 with demonstrated antiviral activity in man.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with MarketBeat.com's FREE daily email newsletter.